当前位置:产品中心 > 抗体 > Biosimilar抗体 > 免疫检查点 > Anti-CTLA-4/PD-1 hIgG1 Bispecific Antibody(Cadonilimab)
Anti-CTLA-4/PD-1 hIgG1 Bispecific Antibody(Cadonilimab)
基本信息

产品编号:GM-60293AB

产品名称:Anti-CTLA-4/PD-1 hIgG1 Bispecific Antibody(Cadonilimab)

目录价:询价


产品配图.jpg

规格货号

GM-60293AB-10           10 μg

GM-60293AB-100         100 μg

GM-60293AB-1000       1mg

产品简介

Species Reactivity      Human

Specificity                   Detects human CTLA-4 and PD-1.

Source/Isotype           Monoclonal human IgG1, κ

Application                 Binding activation: 100 pg/mL-100 μg/mL

Background                PD-1 is an immunosuppressive receptor expressed by activated T and B cells and plays a key role in the regulation of the immune response to tumor antibodies and autoantigens. The interaction between PD-1 and its ligand PD-L1 or PD-L2 in neighboring cells can inhibit the conduction of TCR signaling pathway and the effects of TCR-mediated cell proliferation, transcriptional activation, and cytokine production. Therapeutic antibodies and Fc fusion proteins used to block PD-1/PD-L1 interactions have been shown to be promising in clinical trials for the treatment of various cancers.

                                     CTLA-4, also known as CD152, is an immunosuppressive receptor that is constitutively expressed on regulatory T cells (TreGs). It plays a key role in the regulation of immune response. When CTLA4 is upregulated on T cell surface, T cells bind to CD80(B7-1) or CD86(B7-2) with a higher affinity than CD28's positive costimulatory signal, thus inducing T cell nonreactivity. Antibodies and Fc fusion proteins that block the interaction of CTLA4/CD80 and CD86 have been shown to have promising applications in clinical trials against various cancers.

Storage                        Store at +4℃ short term (1-2 weeks). Store at -20℃ long term

Formulation                Phosphate-buffered solution, pH 7.2.

数据展示

/ueditor/image/20240515/1715741742720715/374333e8b6555ced3084f27e7928ebfd.png

当前位置:产品中心 > 抗体 > Biosimilar抗体 > Anti-CTLA-4/PD-1 hIgG1 Bispecific Antibody(Cadonilimab)

Anti-CTLA-4/PD-1 hIgG1 Bispecific Antibody(Cadonilimab)
基本信息

产品编号:GM-60293AB

产品名称:Anti-CTLA-4/PD-1 hIgG1 Bispecific Antibody(Cadonilimab)

目录价:询价


产品配图.jpg

规格货号

GM-60293AB-10           10 μg

GM-60293AB-100         100 μg

GM-60293AB-1000       1mg

产品简介

Species Reactivity      Human

Specificity                   Detects human CTLA-4 and PD-1.

Source/Isotype           Monoclonal human IgG1, κ

Application                 Binding activation: 100 pg/mL-100 μg/mL

Background                PD-1 is an immunosuppressive receptor expressed by activated T and B cells and plays a key role in the regulation of the immune response to tumor antibodies and autoantigens. The interaction between PD-1 and its ligand PD-L1 or PD-L2 in neighboring cells can inhibit the conduction of TCR signaling pathway and the effects of TCR-mediated cell proliferation, transcriptional activation, and cytokine production. Therapeutic antibodies and Fc fusion proteins used to block PD-1/PD-L1 interactions have been shown to be promising in clinical trials for the treatment of various cancers.

                                     CTLA-4, also known as CD152, is an immunosuppressive receptor that is constitutively expressed on regulatory T cells (TreGs). It plays a key role in the regulation of immune response. When CTLA4 is upregulated on T cell surface, T cells bind to CD80(B7-1) or CD86(B7-2) with a higher affinity than CD28's positive costimulatory signal, thus inducing T cell nonreactivity. Antibodies and Fc fusion proteins that block the interaction of CTLA4/CD80 and CD86 have been shown to have promising applications in clinical trials against various cancers.

Storage                        Store at +4℃ short term (1-2 weeks). Store at -20℃ long term

Formulation                Phosphate-buffered solution, pH 7.2.

数据展示

/ueditor/image/20240515/1715741742720715/374333e8b6555ced3084f27e7928ebfd.png

Tel: 400-627-9288
留言咨询
重置
提交
客服
微信
电话
留言
留言咨询
重置
提交